Granted Patent
B2
US 12,337,028 · App. 18/514,838 · Granted Jun 24, 2025
Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
Inventors:
Weijun Shen (San Diego, CA); Pengyu Yang (San Diego, CA); Huafei Zou (San Diego, CA); Peter G. Schultz (Carlsbad, CA)
Assignee:
THE SCRIPPS RESEARCH INSTITUTE
A61K38/22A61K9/0019A61K9/0021A61K38/2278A61K38/26A61K45/06A61K47/54A61K47/542A61K47/543A61K47/554A61K47/60A61K9/703
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Methods and compositions are provided for extending the half-life of a therapeutic agent. A modified therapeutic agent (mTA) comprises a therapeutic agent, a staple, and a half-life extending molecule. The mTAs disclosed herein may be used to treat a disease or a condition in a subject in need thereof.
Claims (9)
1. A method for treating obesity in a human subject in need thereof, the method comprising administering to the human subject a composition comprising a peptide selected from SEQ ID NOs: 30-32.
2. The method of claim 1 , wherein the peptide is SEQ ID NO: 30.
3. A method for treating Crohn's disease, ulcerative colitis, or short bowel syndrome, in a human subject in need thereof, the method comprising administering to the human subject a composition comprising a peptide selected from SEQ ID NOs: 42-51.
4. The method of claim 3 , wherein the peptide is SEQ ID NO: 49.
5. The method of claim 3 , wherein the peptide is SEQ ID NO: 42.
6. A method for treating obesity in a human subject in need thereof, the method comprising administering to the human subject a composition comprising a peptide selected from SEQ ID NOs: 35-41 and 51-52.
7. The method of claim 6 , wherein the peptide is SEQ ID NO: 37.
8. The method of claim 6 , wherein the peptide is SEQ ID NO: 38.
9. The method of claim 6 , wherein the peptide is SEQ ID NO: 39.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 25, 2025
From: SHEN, WEIJUN; YANG, PENGYU; ZOU, HUAFEI; SCHULTZ, PETER G.
To: THE SCRIPPS RESEARCH INSTITUTE
Reel/Frame 070626/0819 →
Continuity (5)
Continuation
15104807
Provisional Application
61917816
· Dec 18, 2013
References Cited (269)
US 3773919A
· Boswell et al.
· 1973
[cited by applicant]
US 3854480A
· Zaffaroni
· 1974
[cited by applicant]
US 3887699A
· Yolles
· 1975
[cited by applicant]
US 4452775A
· Kent
· 1984
[cited by applicant]
US 4485045A
· Regen
· 1984
[cited by applicant]
US 4544545A
· Ryan et al.
· 1985
[cited by applicant]
US 4675189A
· Kent et al.
· 1987
[cited by applicant]
US 5133974A
· Paradissis et al.
· 1992
[cited by applicant]
US 5407686A
· Patel et al.
· 1995
[cited by applicant]
US 5654010A
· Johnson et al.
· 1997
[cited by applicant]
US 5736152A
· Dunn
· 1998
[cited by applicant]
US 5750497A
· Havelund et al.
· 1998
[cited by applicant]
US 5759807A
· Breece et al.
· 1998
[cited by applicant]
US 5811395A
· Schwabe et al.
· 1998
[cited by applicant]
US 5863552A
· Yue
· 1999
[cited by applicant]
US 5866538A
· Norup et al.
· 1999
[cited by applicant]
US 6011007A
· Havelund et al.
· 2000
[cited by applicant]
US 6051551A
· Hughes et al.
· 2000
[cited by applicant]
US 6268343B1
· Knudsen et al.
· 2001
[cited by applicant]
US 6372716B1
· Bush et al.
· 2002
[cited by applicant]
US 6444641B1
· Flora
· 2002
[cited by applicant]
US 6566329B1
· Meyn et al.
· 2003
[cited by applicant]
US 6685940B2
· Andya et al.
· 2004
[cited by applicant]
US 6869930B1
· Havelund et al.
· 2005
[cited by applicant]
US 6890518B2
· Patton et al.
· 2005
[cited by applicant]
US 7960506B2
· Nash
· 2011
[cited by applicant]
US 7981998B2
· Nash
· 2011
[cited by applicant]
US 7981999B2
· Nash
· 2011
[cited by applicant]
US 8071541B2
· Arora et al.
· 2011
[cited by applicant]
US 8129343B2
· Lau et al.
· 2012
[cited by applicant]
US 8217145B2
· Wang et al.
· 2012
[cited by applicant]
US 8399405B2
· Nash et al.
· 2013
[cited by applicant]
US 8420598B2
· Lee et al.
· 2013
[cited by applicant]
US 8486384B2
· Shen et al.
· 2013
[cited by applicant]
US 8524653B2
· Nash et al.
· 2013
[cited by applicant]
US 8637686B2
· Nash
· 2014
[cited by applicant]
US 8735539B2
· Kraynov et al.
· 2014
[cited by applicant]
US 8808694B2
· Nash et al.
· 2014
[cited by applicant]
US 9254311B2
· Bancel et al.
· 2016
[cited by applicant]
US 9474780B2
· Bokvist et al.
· 2016
[cited by applicant]
US 20050176108A1
· Kim et al.
· 2005
[cited by applicant]
US 20050192217A1
· Muhlradt et al.
· 2005
[cited by applicant]
US 20080305519A1
· Lin et al.
· 2008
[cited by applicant]
US 20090186817A1
· Ghosh et al.
· 2009
[cited by applicant]
US 20090239784A1
· Jonassen et al.
· 2009
[cited by applicant]
US 20090275519A1
· Nash et al.
· 2009
[cited by applicant]
US 20090326192A1
· Nash et al.
· 2009
[cited by applicant]
US 20100029554A1
· Ghosh et al.
· 2010
[cited by applicant]
US 20110046056A1
· Bianchi et al.
· 2011
[cited by applicant]
US 20110144303A1
· Nash et al.
· 2011
[cited by applicant]
US 20110223149A1
· Nash et al.
· 2011
[cited by applicant]
US 20110243942A1
· Wang
· 2011
[cited by applicant]
US 20120178700A1
· Nash et al.
· 2012
[cited by applicant]
US 20130023646A1
· Nash et al.
· 2013
[cited by applicant]
US 20130040884A1
· Lau et al.
· 2013
[cited by applicant]
US 20140148390A1
· Haupts et al.
· 2014
[cited by applicant]
US 20180207276A1
· Shen
· 2018
[cited by applicant]
US 20180228907A1
· Crew et al.
· 2018
[cited by applicant]
US 20190000928A1
· Shen et al.
· 2019
[cited by applicant]
US 20220072104A1
· Shen et al.
· 2022
[cited by applicant]
US 20230057847A1
· Shen et al.
· 2023
[cited by applicant]
CA 2924109A1
· 2015
[cited by applicant]
CN 104582736A
· 2015
[cited by applicant]
CN 104945500A
· 2015
[cited by applicant]
CN 105792851A
· 2016
[cited by applicant]
CN 106029087A
· 2016
[cited by applicant]
CN 107921098A
· 2018
[cited by applicant]
EP 0133988A2
· 1985
[cited by applicant]
WO WO2004100997A2
· 2004
[cited by applicant]
WO WO2006066258A2
· 2006
[cited by applicant]
WO WO2006097537A2
· 2006
[cited by applicant]
WO WO2007109135A2
· 2007
[cited by applicant]
WO WO2008057298A2
· 2008
[cited by applicant]
WO WO2010011439A2
· 2010
[cited by applicant]
WO WO2010096052A1
· 2010
[cited by applicant]
WO WO2010096142A1
· 2010
[cited by applicant]
WO WO2011039096A1
· 2011
[cited by applicant]
WO WO2012003995A1
· 2012
[cited by applicant]
WO WO2012006598A2
· 2012
[cited by applicant]
WO WO2012011752A2
· 2012
[cited by applicant]
WO WO2012024452A2
· 2012
[cited by applicant]
WO WO2012088116A2
· 2012
[cited by applicant]
WO WO2012088379A2
· 2012
[cited by applicant]
WO WO2012149563A1
· 2012
[cited by applicant]
WO WO2013004607A1
· 2013
[cited by applicant]
WO WO2013007563A1
· 2013
[cited by applicant]
WO WO2013100704A1
· 2013
[cited by applicant]
WO WO2013130683A2
· 2013
[cited by applicant]
WO WO2013192131A1
· 2013
[cited by applicant]
WO WO2014059213A1
· 2014
[cited by applicant]
WO WO2015038938A1
· 2015
[cited by applicant]
WO WO2015095406A1
· 2015
[cited by applicant]
WO WO2015095684A1
· 2015
[cited by applicant]
WO WO2016111971A1
· 2016
[cited by applicant]
WO WO2016149501A2
· 2016
[cited by applicant]
WO WO2017007612A1
· 2017
[cited by applicant]
WO WO2017024317A2
· 2017
[cited by applicant]
WO WO2017024318A1
· 2017
[cited by applicant]
WO WO2017210600A1
· 2017
[cited by applicant]
WO WO2018119448A1
· 2018
[cited by applicant]
WO WO2018148440A1
· 2018
[cited by applicant]
WO WO2018148443A1
· 2018
[cited by applicant]
WO WO2018187401A1
· 2018
[cited by applicant]
WO WO2019165229A1
· 2019
[cited by applicant]
WO WO2020077278A1
· 2020
[cited by applicant]
WO WO2020207477A1
· 2020
[cited by applicant]
WO WO2021093883A1
· 2021
[cited by applicant]
WO WO2022257979A1
· 2022
[cited by applicant]
NHS (<https://www.nhs.uk/conditions/obesity/> May 2019) (Year: 2019).
[cited by examiner]
Merck Manual (https://www.merckmanuals.com/home/digestive-disorders/tumors-of-the-digestive-system/colorectal-cancer Jul. 2019) (Year: 2019).
[cited by examiner]
Merck Manual (<https://www.merckmanuals.com/professional/musculoskeletal-and-connective-tissue-disorders/joint-disorders/osteoarthritis-oa> May 2020) (Year: 2020).
[cited by examiner]
Psoriasis (Merck Manual at URL merckmanuals.com/professional/dermatologic-disorders/psoriasis-and-scaling-diseases/psoriasis?query=psoriasis 2024) (Year: 2024).
[cited by examiner]
Who Cardiovascular guidelines “Prevention of Cardiovascular Disease: Guidelines for assessment and management of cardiovascular risk” accessed at Mar. 16, 2015 at URL who.intJcardiovascular_diseases/guidelines/Full%20te…
[cited by examiner]
Korczyn, A.D. and Nussbaum, M., “Emerging Therapies in the Pharmacological Treatment of Parkinson's Disease,” Drugs 62:775-786 (2002) (Year: 2002).
[cited by examiner]
Margolis , R. “Diagnosis of Huntington's Disease,”Clin. Chem. 49:1726-32 (2003) (Year: 2003).
[cited by examiner]
Inflammatory disorders from Merck Manual, pp. 1-4. Accessed Aug. 30, 2020 (Year: 2020).
[cited by examiner]
Dermatitis from Merck Manual, pp. 1-4. Accessed Aug. 30, 2020. (Year: 2020).
[cited by examiner]
Inflammation from Merck Manual, pp. 1-3. Accessed Aug. 30, 2020. (Year: 2020).
[cited by examiner]
Aicart-Ramos et al. Protein palmitoylation and subcellar trafficking. Biochim Biophys Acta 1808:2981-2994 (2011).
[cited by applicant]
Altschul et al., Gapped BLAST and PSI-BLAST: A New Generation Of Protein Database Search Programs. Nucleic Acids Research 25(17):3389-3402 (Sep. 1, 1997).
[cited by applicant]
Amso et al., A Peptide Engineering Platform for PEG-FA Stapled Long-acting Peptide Hormones. (2020).
[cited by applicant]
Backer et al. Chapter 16: Cysteine-Containing Fusion Tag for Site-Specific Conjugation of Therapeutic and Imaging Agents to Targeting Proteins, Peptide-Based Drug Design Methods and Protocols, Springer Protocols, pp. 27…
[cited by applicant]
Bader, et al., Bioorganic synthesis of lipid-modified proteins for the study of signal transduction. Nature 403:223-226 (Jan. 13, 2000).
[cited by applicant]
Baosheng. Peptide PEGylation: The Next Generation Linking peptides to polythylene glycol, or PEGylation, has helped improve pharmaceutical therapeutics in several ways. A wave of new techniques is now ushering in furthe…
[cited by applicant]
Bird et al. Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic. PNAS USA 107(32):14093-14098 (2010).
[cited by applicant]
Chalker et al. Chemical modification of proteins at cysteine: opportunities in chemistry and biology. Chem Asian J 4(5):630-640 (2009).
[cited by applicant]
Chang et al. Stapled α-helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. PNAS USA 110(36):E3445-E3454 (2013).
[cited by applicant]
Cheng et al. Design, synthesis, characterization and in-vivo activity of a novel salmon calcitonin conjugate containing a novel PEG-lipid moiety. J Pharm Pharmacol 62(3):296-304 (Mar. 2010).
[cited by applicant]
Cheng et al. Lipeo-sCT: A novel reversible lipidized salmon calcitonin derivative, its biophysical properties and hypocalcemic activity. Euro J Pharm Sci 37(2):151-159 (May 12, 2009).
[cited by applicant]
Coskun et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Clinical Trial 18:3-14 (2018).
[cited by applicant]
Day et al., A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol 5(10):749-757 (2009).
[cited by applicant]
Day et al. Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents. Biopolymers, 98(5):443-450 (2012).
[cited by applicant]
Druce et al. Investigation of Structure-Activity Relationships of Oxyntomodulin (Oxm) Using Oxm Analogs. Endocrinology 150(4):1712-1721 (Apr. 2009).
[cited by applicant]
Finan et al., Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans. Sci Transl Med 5(209):209ra151 (2013).
[cited by applicant]
Guldenhaupt et al. Secondary structure of lipidated Ras bound to lipid bilayer. FEBS J 275:5910-5918 (2008).
[cited by applicant]
Havelund et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res 21(9):1498-1504 (Aug. 2004).
[cited by applicant]
Hossain et al. Chimeric relaxin peptides highlight the role of the A-chain in the function of H2 relaxin. Peptides 35:102-106 (May 2012).
[cited by applicant]
Hossain et al. The Minimal Active Structure of Human Relaxin-2. J Biol Chem 286(43):37555-37565 (2011).
[cited by applicant]
Janout et al., Bioconjugate-Based Molecular Umbrellas. Bioconjugate Chemistry, 20(2):183-192 (E-Pub Nov. 20, 2008).
[cited by applicant]
Joregensen et al., Oxyntomodulin differentially affects glucagon-like peptide-1 receptor beta-arrestin recruitment and signaling through Gas. The Journal of Pharmacology and Experimental Therapeutics. 322(1):148-154 (20…
[cited by applicant]
Karlin et al., Applications And Statistics For Multiple High-Scoring Segments In Molecular Sequences. PNAS USA 90(12):5873-5877 (Jun. 15, 1993).
[cited by applicant]
Koonin et al., Chapter 2: Evolutionary Concept in Genetics and Genomics. Sequence—Evolution—Function: Computational Approaches in Comparative Genomics. Boston: Kluwer Academic (2003).
[cited by applicant]
Lau et al., Peptide stapling techniques based on different macrocyclisation chemistries. Chemical Society Reviews. 44(1):91-102 (2015).
[cited by applicant]
Lear et al., Chapter 8: Engineering PEG-fatty acid stapled, long-acting peptide agonists for G protein-coupled receptors. Methods in Enzymology 622:183-200 (2019).
[cited by applicant]
Lear et al., Engineering of a Potent, Long-Acting NPY2R Agonist for Combination with a Glp- 1R Agonist as a Multi-Hormonal Treatment for Obesity. J Med Chem 63(17):9660-9671 (2020).
[cited by applicant]
Lear et al., Peptide Engineering Strategies for Long-Acting Peptide Hormones. (2019) Abstract.
[cited by applicant]
Lorenz et al. Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity. Bioorg Med Chem Lett 23(14):4011-4018 (May 16, 2013).
[cited by applicant]
Metra et al. Effect of Serelaxin on Cardiac, Renal, and Hepatic Biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) Development Program. J Am Coll Cardiol 61(2):196-206 (Jan. 15, 2013).
[cited by applicant]
Muller et al. Chapter 2: Peptide carrier conjugation, Synthetic Peptides as Antigens, Laboratory Techniques in Biochemstry and Molecular Biology. 28:79-131 (1999).
[cited by applicant]
Muppidi et al., Design and Synthesis of Potent, Long-Acting Lipidated Relaxin-2 Analogs. Bioconjugate Chem. 30:83-89 (Dec. 2018).
[cited by applicant]
Muppidi et al., Design of Potent and Proteolytically Stable Oxyntomodulin Analogs. ACS Chem. Biol. 11:324-328 (2016).
[cited by applicant]
Muppidi et al. Rational design of proteolytically stable, cell-permeable peptide-based selective Mcl-1 inhibitors. J. Am. Chem. Soc. 134:14734-14737 (Aug. 2012).
[cited by applicant]
Pan et al. Design of a Long Acting Peptide Functioning as Both a Glucagon-like Peptide-1 Receptor Agonist and a Glucagon Receptor Antagonist. J Biol Chem 281(18):12506-12515 (May 5, 2008).
[cited by applicant]
Patterson et al. Functional association of the N-terminal residues with the central region in glucagon-related peptides. J. Pept. Sci. 17:659-666 (2011).
[cited by applicant]
PCT/US2014/055457 International Search Report and Written Opinion dated Dec. 23, 2014.
[cited by applicant]
PCT/US2014/070977 International Search Report and Written Opinion dated Mar. 27, 2015.
[cited by applicant]
PCT/US2016/022880 International Search Report and Written Opinion dated Oct. 7, 2016.
[cited by applicant]
PCT/US2016/037834 International Search Report and Written Opinion dated Oct. 26, 2016.
[cited by applicant]
Pflimlin et al., Design of a Long-Acting and Selective MEG-Fatty Acid Stapled Prolactin-Releasing Peptide Analog. ACS Med. Chem. Lett. 10:1166-1172 (2019).
[cited by applicant]
Pflimlin et al., Engineering a Potent, Long Acting and Periphery-Restricted Oxytocin Receptor Agonist with Anorexigenic and Body Weight Reducing Effects. J. Med. Chem. 63(1):382-390 (2020).
[cited by applicant]
Pollaro et al., Strategies to prolong the plasma residence time of peptide drugs. Med. Chem. Commun. 1:319-324 (2010).
[cited by applicant]
Rost. Twilight zone of protein sequence alignments. Protein engineering 12(2):85-94 (1999).
[cited by applicant]
Santoprete et al. DPP-IV-resistant, long-acting oxyntomodulin derivatives. J Pep Sci 17:270-280 (2011).
[cited by applicant]
Schultz et al. General Approach to the Synthesis of Short a-Helical Peptides. J. Am. Chem. Soc. 113:9391-9392 (1991).
[cited by applicant]
Shah. Bioconjugates: The Adaptable Challenge. BioPharm International The Science & Business of Biopharmaceuticals 26(1):1-4 (Jan. 1, 2013).
[cited by applicant]
Soloff et al. Cloning, characterization, and expression of the rat relaxin gene. Gene 323:149-155 (2003).
[cited by applicant]
Teerlink, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 381:29-39 (Jan. 2013).
[cited by applicant]
Trussel et al. New strategy for the extension of the serum half-life of antibody fragments. Bioconjug Chem. 20(12):2286-92 (2009).
[cited by applicant]
Underwood et al. Crystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 Receptor. J Biol Chem 285(1):723-730 (Jan. 1, 2010).
[cited by applicant]
U.S. Appl. No. 14/917,689 Final Office Action dated Dec. 22, 2017.
[cited by applicant]
U.S. Appl. No. 14/917,689 Office Action dated May 30, 2017.
[cited by applicant]
U.S. Appl. No. 15/104,807 Office Action dated Nov. 27, 2017.
[cited by applicant]
U.S. Appl. No. 15/735,898 Final Office Action dated Jun. 22, 2020.
[cited by applicant]
U.S. Appl. No. 15/735,898 Final Office Action dated May 25, 2021.
[cited by applicant]
U.S. Appl. No. 15/735,898 Office Action dated Jan. 8, 2020.
[cited by applicant]
U.S. Appl. No. 16/000,829 Office Action dated Aug. 27, 2020.
[cited by applicant]
U.S. Appl. No. 16/000,829 Office Action dated Mar. 5, 2020.
[cited by applicant]
U.S. Appl. No. 16/405,594 Office Action dated Aug. 12, 2020.
[cited by applicant]
U.S. Appl. No. 17/317,631 Office Action dated Dec. 23, 2022.
[cited by applicant]
U.S. Appl. No. 17/317,631 Office Action dated May 12, 2023.
[cited by applicant]
U.S. Appl. No. 17/485,171 Office Action dated May 10, 2023.
[cited by applicant]
Verdine et al. Chapter 1: Stapled Peptides for Intracellular Drug Targets. Methods in Enzymology 503:3-33 (Dec. 2012).
[cited by applicant]
Wade et al. The Chemical Synthesis of Relaxin and Related peptides: A Historical Perspective. Ann. N.Y. Acad. Sci. 1160:11-15 (2009).
[cited by applicant]
Walensky et al. Hydrocarbon-Stapled Peptides: Principles, Practice, and Progress. J Med Chem 57:6275-6288 (2014).
[cited by applicant]
Webber et al., Genes and homology. Current Biology 14(9):R332-R333 (2004).
[cited by applicant]
Wisniewski et al., Synthesis and Pharmacological Characterization of Novel Glucagon-like Peptide-2 (GLP-2) Analogues with Low Systemic Clearance. J Med Chem 59:3129-3139 (Mar. 2016).
[cited by applicant]
Wu et al. Addition of a cysteine to glucagon-like peptide-1 (GLP-1) conjugates GLP-1 to albumin in serum and prolongs GLP-1 action in vivo. Reg Pept 164(2):83-89 (2010).
[cited by applicant]
Yang et al. Engineering a long-acting, potent GLP-1 analog for microstructure-based transdermal delivery. PNAS USA 113(15):4140-4145 (2016).
[cited by applicant]
Yang et al., New Generation Oxyntomodulin Peptides with Improved Pharmacokinetic Profiles Exhibit Weight Reducing and Anti-Steatotic Properties in Mice. Bioconjugate Chem. 31(4):1167-1176 (2020).
[cited by applicant]
U.S. Appl. No. 17/485,171 Office Action dated May 28, 2024.
[cited by applicant]
Backus et al. Proteome-wide covalent ligand discovery in native biological systems. Nature 534(7608):570-574 (2016).
[cited by applicant]
Bondeson, et al., Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat Chem Biol 11(8):611-617 (Aug. 2015).
[cited by applicant]
Bondeson et al. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead. Cell Chem Biol 25:78-87.e5 (2018).
[cited by applicant]
Buckley et al. Small-molecule inhibitors of the interaction between the E3 ligase VHL and HIF1α. Angew Chem Int Ed Engl 51:11463-11467 (2012).
[cited by applicant]
Cal et al. Cysteine-selective reactions for antibody conjugation. Angewandte Chemi International Edition 53:10585-10587 (2014).
[cited by applicant]
Chen et al. Plant E3 Ligases: Flexible Enzymes in a Sessile World. Molecular Plant 6(5): 1388- 1404 (2013).
[cited by applicant]
Co-pending U.S. Appl. No. 15/104,807, inventors Shen; Weijun et al., filed Jun. 15, 2016.
[cited by applicant]
Co-pending U.S. Appl. No. 15/735,898, inventors Shen; Weijun et al., filed Dec. 12, 2017.
[cited by applicant]
Co-pending U.S. Appl. No. 16/000,829, inventors Shen; Weijun et al., filed Jun. 5, 2018.
[cited by applicant]
Co-pending U.S. Appl. No. 17/317,631, inventors Shen; Weijun et al., filed May 11, 2021.
[cited by applicant]
Co-pending U.S. Appl. No. 17/485,171, inventors Shen; Weijun et al., filed Sep. 24, 2021.
[cited by applicant]
Co-pending U.S. Appl. No. 17/782,560, inventors Shen; Weijun et al., filed Jun. 3, 2022.
[cited by applicant]
Co-pending U.S. Appl. No. 17/782,573, inventors Shen; Weijun et al., filed Jun. 3, 2022.
[cited by applicant]
Co-pending U.S. Appl. No. 18/366,653, inventors Shen; Weijun et al., filed Aug. 7, 2023.
[cited by applicant]
Co-pending U.S. Appl. No. 18/568,244, inventors Shen; Weijun et al., filed Dec. 7, 2023.
[cited by applicant]
Deshaies et al.RING Domain E3 Ubiquitin Ligases. Annual Review Of Biochemistry 78(1):399-434 (2009).
[cited by applicant]
Filippakopoulos et al.: Selective inhibition of BET bromodomains. Nature 468:1067-1073 (2010).
[cited by applicant]
Gadd et al. Structural basis of PROTAC cooperative recognition for selective protein degradation. Nat Chem Biol 13:514-521 (2017).
[cited by applicant]
Huang et al. A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi- kinase Degrader. Cell Chem Biol 25:88-99 (2018).
[cited by applicant]
Ito et al. Identification of a primary target of thalidomide teratogenicity. Science 327:1345-1350 (2010).
[cited by applicant]
Jin et al., A family of diverse Cul4-Ddb1-interacting proteins includes Cdt2, which is required for S phase destruction of the replication factor Cdt1. Molecular Cell. 23(5):709-721 (2006).
[cited by applicant]
Lear et al. Recombinant Expression and Stapling of a Novel Long-Acting GLP-1R Peptide Agonist. Molecules 25(11):2508 (2020).
[cited by applicant]
Nabet et al. The dTAG system for immediate and target-specific protein degradation. Nat Chem Biol 14:431-441 (2018).
[cited by applicant]
PCT/US2019/055958 International Search Report and Written Opinion dated Feb. 3, 2020.
[cited by applicant]
Raina et al. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. PNAS USA 113:7124-7129 (2016).
[cited by applicant]
Soucy et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458:732-736 (2009).
[cited by applicant]
U.S. Appl. No. 16/600,326 Office Action dated Apr. 27, 2021.
[cited by applicant]
U.S. Appl. No. 16/600,326 Office Action dated Dec. 2, 2021.
[cited by applicant]
U.S. Appl. No. 16/600,326 Office Action dated May 23, 2022.
[cited by applicant]
U.S. Aool. No. 17/485,171 Office Action dated Nov. 3, 2023.
[cited by applicant]
Vassilev et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303:844-848 (2004).
[cited by applicant]
Weerapana et al. Quantitative reactivity profiling predicts functional cysteines in proteomes. Nature 468:790-795 (2010).
[cited by applicant]
Winter et al. Drug Development. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 348:1376-1381 (2015).
[cited by applicant]
Xu et al. ProLuCID: An improved SEQUEST-like algorithm with enhanced sensitivity and specificity. J Proteomics 129:16-24 (2015).
[cited by applicant]
Yang et al. Stapled, Long-Acting Glucagon-like Peptide 2 Analog with Efficacy in Dextran Sodium Sulfate Induced Mouse Colitis Models. J Med Chem 61(7):3218-3223 (2018).
[cited by applicant]
Zhang et al. Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16. Nature Chemical Biology 15:737-746 (2019).
[cited by applicant]
U.S. Appl. No. 18/366,653 Office Action dated Nov. 29, 2024.
[cited by applicant]
Yang, Yifang et al. Design of potent and proteolytically stable biaryl-stapled GLP-1R/GIPR peptide dual agonists. ACS chemical biology 17(5):1249-1258 (2022).
[cited by applicant]
Cited By (1)